Novel CS1-CAR-T cells and bispecific CAR-T cells targeting both CS1-and BCMA antigens represent one of the approaches to increase the efficacy of CAR-T cells when tumor antigen heterogeneity is present or due to other mechanisms [31]. This evidence concerns the gene TNFRSF17 and neoplasm.